BMS's two Phase 3 autism irritability trials of KarXT + KarX-EC remain in recruiting statusNov 12Weekly roundup, 3 itemsBristol Myers Squibbxanomeline and trospium chlorideUpdated
IDEAYA completes darovasertib NDA, halts Phase 3 OptimUM-010 for enrollment issuesNov 3Quarterly updateAlector, Inc.Allogene Therapeutics
Wave Life Sciences details Q3 2026 progress on WVE-006, WVE-007, WVE-008 pipelineOct 28Quarterly updateBristol Myers SquibbEli LillyUpdated
Zai Lab registers Phase 3 trial for ZL-1310 in lung cancer and real-world KarXT study in ChinaSep 3Weekly roundup, 2 itemsxanomeline and trospium chlorideZai Lab (Shanghai) Co., Ltd.
BMS registers new deucravacitinib continuation study; prior week's trial results still standAug 27Weekly roundup, 5 itemsBristol Myers Squibbdeucravacitinib
Zai Lab reports Q2 2026 results, advances zoci and ZL-1503 toward key milestonesAug 6Quarterly updateZai Lab (Shanghai) Co., Ltd.ZL-1503
Karuna/BMS opens Phase 3 KarXT relapse prevention trial in schizophreniaJul 7Weekly roundup, 2 itemsBristol Myers Squibbpomalidomide
BMS posts PRIME-HCC results; adds SOTYKTU label update, Phase 3 lung trialJul 2Weekly roundup, 7 itemsBristol Myers Squibbcisplatin